Clinical and Infection Prevention Applications of Severe Acute Respiratory Syndrome Coronavirus 2 Genotyping: an Infectious Diseases Society of America/American Society for Microbiology Consensus Review Document.
Clinical and Infection Prevention Applications of Severe Acute Respiratory Syndrome Coronavirus 2 Genotyping: an Infectious Diseases Society of America/American Society for Microbiology Consensus Review Document.
复制标题
DOI：
10.1128/jcm.01659-21
复制
发表时间：
2022-01-19
影响因子：
9.4
通讯作者：
Lee FM
中科院分区：
文献类型：
--
作者：
Greninger AL;Dien Bard J;Colgrove RC;Graf EH;Hanson KE;Hayden MK;Humphries RM;Lowe CF;Miller MB;Pillai DR;Rhoads DD;Yao JD;Lee FM
严重急性呼吸综合征冠状病毒2 （SARS-CoV-2）出现在病原体基因组学成熟的世界中，在撰写本文时，已有超过200万个基因组测序。影响疫苗和治疗效果的更多可传播变异的出现，导致人们对SARS-CoV-2的进化产生了广泛的兴趣。临床医生也渴望利用SARS-CoV-2基因分型提供的信息，而不仅仅是为了监测目的。在此，我们回顾了SARS-CoV-2基因分型在临床护理中的潜在作用。该综述涵盖了SARS-CoV-2基因分型的临床用例、SARS-CoV-2基因分型方法、检测验证和监管要求、实验室临床报告以及临床SARS-CoV-2测序中的新问题。虽然SARS-CoV-2基因分型的临床应用目前有限，但随着有关疫苗和治疗效果的数据不断出现，快速的技术变革以及实时解释变异的能力不断增强，预示着SARS-CoV-2基因分型在临床护理中的作用越来越大。
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) emerged into a world of maturing pathogen genomics, with more than 2 million genomes sequenced at the time of writing. The rise of more transmissible variants of concern that impact vaccine and therapeutic effectiveness has led to widespread interest in SARS-CoV-2 evolution. Clinicians are also eager to take advantage of the information provided by SARS-CoV-2 genotyping beyond surveillance purposes. Here, we review the potential role of SARS-CoV-2 genotyping in clinical care. The review covers clinical use cases for SARS-CoV-2 genotyping, methods of SARS-CoV-2 genotyping, assay validation and regulatory requirements, and clinical reporting for laboratories, as well as emerging issues in clinical SARS-CoV-2 sequencing. While clinical uses of SARS-CoV-2 genotyping are currently limited, rapid technological change along with a growing ability to interpret variants in real time foretells a growing role for SARS-CoV-2 genotyping in clinical care as continuing data emerge on vaccine and therapeutic efficacy.